Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITY OF RIJEKA FACULTY OF MEDICINE currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, REDDIG, PETER J, and is situated within 1 distinct art unit. The 1 pending office action represents the entirety of the company's current prosecution activity in this sector. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is highly focused on a single technical and administrative channel.
REDDIG, PETER J is the busiest examiner for the portfolio, holding 1 busiest examiner pending office action. Practitioners must tailor their responses to the specific preferences of this 1 distinct examiner to resolve the 1 pending office action. The 1 distinct art unit suggests a specialized focus within the broader biotechnology field. Successfully clearing the 1 pending office action will depend entirely on the dialogue with the 1 distinct examiner in the 1 distinct art unit. The 1 busiest examiner pending case requires a precise technical argument to satisfy the 1 distinct art unit standards. Resolving the 1 pending office action is the primary objective for the current biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | REDDIG, PETER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | REDDIG, PETER J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY OF RIJEKA FACULTY OF MEDICINE has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Peter J Reddig has the most, with 1 of UNIVERSITY OF RIJEKA FACULTY OF MEDICINE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
